Hanmi Pharma said it has signed a strategic agreement with its U.S. partner company, Assertio Holdings, which previously acquired Spectrum Pharmaceuticals, to re-acquire the rights to Rolontis, a long-acting neutropenia treatment and Korea's 33rd novel drug, for the Asian and African markets.Rolonti
Takeda Korea said the National Health Insurance will reimburse its adult acquired hemophilia A (AHA) treatment Objzur Inj (susoctocog alpha) starting Thursday.Obizur is Korea's only blood clotting factor VIII treatment for adult AHA. It won the Ministry of Food and Drug Safety approval in March last
BNC Korea said Thursday that it has signed a joint research and development agreement with SML Biopharm to develop a GLP1 agonist for treating diabetes and obesity using mRNA technology.Under the agreement, SML Biopharm will utilize its mRNA platform expression technology to express target genes in
Ildong Pharmaceutical has received material patents in China and Japan for its metabolic disease drug candidate, ID110521156, which is being developed through its subsidiary Yunovia.ID110521156 is the GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist) family of drugs and acts as an an
Pfizer Korea and Hanlim MS said they entered into a co-marketing agreement for the drug Xeljanz (ingredient: tofacitinib citrate), a drug used in the treatment of various autoimmune diseases.This collaboration aims to expand the availability and benefits of Xeljanz to a wider patient demographic thr
CHA Vaccine Institute, a subsidiary of CHA Biotech, has disclosed the top-line results from the phase 1 clinical trial of its third-generation hepatitis B vaccine candidate, CVI-HBV-002, which showed that the candidate had higher efficacy compared to currently available vaccines. The announcement pr
CG Bio, a regenerative medicine company, said Wednesday that it has launched Easydew MD cream 200g, which strengthens the skin barrier.The skin barrier is the outer layer of the skin that protects the skin from external threats such as infectious agents, chemicals, systemic toxins, and allergens.Eas
AstraZeneca Korea said Wednesday that it has signed an agreement with HK inno.N, a Kosdaq-listed healthcare company, to co-promote Forxiga's combination drugs, Xigduo XR (dapagliflozin + metformin) and Sidapvia Tab (dapagliflozin + sitagliptin), and to distribute Forxiga (dapagliflozin) in Korea.Und
Celltrion held an orientation for biotech startup companies selected through the Seoul Biohub-Celltrion Open Innovation Program on Tuesday at its Global Biotechnology Research Center in Songdo, Incheon.The Seoul Biohub-Celltrion Open Innovation Program fosters and supports biotech and medical startu
Boehringer Ingelheim Korea said it has commenced a voluntary recall of select batches for Spiriva Respimat (ingredient: tiotropium bromide hydrate), its chronic obstructive pulmonary disease (COPD) and asthma medication.This medication is approved for use as a bronchodilator in the maintenance treat
In a recent media session organized by MSD Korea, a local professor shared insights regarding the efficacy of MSD's Lagevrio (ingredient: molnupiravir) in treating Covid-19, with a particular focus on high-risk groups.As the global community continues to recover from the pandemic, the Covid-19 virus
Bayer Korea's treatment for chronic kidney disease with type 2 diabetes, Kerendia (finerenone), will be covered by health insurance for adult patients starting next month.Kerendia is a first-in-class non-steroidal selective antagonist of the mineralocorticoid receptor, a novel mechanism of action th
Dong-A Pharmaceutical said Tuesday that it has launched a seven-day supply of Orthomol Vital M (for men) and Orthomol Vital F (for women), premium vitamin supplements from German nutraceutical company Orthomol.Orthomol Vital is a nutraceutical brand officially imported and sold in Korea by Dong-A Ph
For the sustainable growth of the domestic biopharmaceutical industry, the government must reform regulations to facilitate businesses’ investment, an industry leader said on Tuesday.To this end, the design of a simple, clear, and predictable drug price system is essential, and the legal status of t
GC Biopharma said Tuesday that it launched a 30-tablet version of its anti-inflammatory drug, Tak-Sen soft cap (naproxen).Tak-Sen is an over-the-counter nonsteroidal anti-inflammatory drug (NSAID) for relieving inflammation and general pain, such as headaches and muscle aches.According to GC Biophar
Daewoong Pharmaceutical said Tuesday that its U.S. partner, AEON Biopharma, has confirmed the safety and efficacy of Daewoong's botulinum toxin (BTX), ABP-450, through phase 2 clinical trials in cervical dystonia and preclinical results in post-traumatic stress disorder (PTSD).AEON Biopharma, a U.S.
The phase 2 clinical trial for preoperative adjuvant therapy, examining the Keytruda-GX-188E-GX-I7/NT-I7 triple combination in the treatment of HPV (human papillomavirus type)-positive head and neck cancer, initiated in 2022, is set to expand to include 56 patients this year.Genexine and NeoImmuneTe
GC Wellbeing, a health/functional food manufacturer, said it signed a new export business agreement with YooYoung Pharmaceutical to enter the Chinese filler market.Under the accord, the two companies aim to develop, produce, market, and sell products specifically for the Chinese filler market, with
SK biopharmaceuticals announced its 2023 fourth quarter and annual financial results, highlighting significant revenue growth and a reduction in operating losses, thanks to increased sales of its epilepsy drug, cenobamate, and cost efficiency measures.The company's revenue for 2023 was 354.9 billion
Daewoong Pharmaceutical said Monday that its drug candidate for idiopathic pulmonary fibrosis (IPF), bersiporocin (DWN12088), has received orphan drug designation ODD) from the European Medicines Agency (EMA).Bersiporocin is a Prolyl-tRNA Synthetase (PRS) inhibitor drug candidate that reduces the ac